Herceptin effective in metastatic breast cancer: Cochrane

The benefits of trastuzumab (Herceptin) outweigh the harms for patients with HER2-positive metastatic breast cancer, say the authors of a new Cochrane Review.

Results from seven trials with almost 1500 patients showed women on trastuzumab were 18% more likely to be alive two years after starting the trial and their cancer progression was reduced by more than a third.

The drug was most effective when used as a first-line treatment in conjunction with taxane-based chemotherapy, the authors from the